Inactive Instrument
Taro Pharmaceutical Industries Ltd. Stock Other OTC
Stocks
IL0010827181
Pharmaceuticals
|
End-of-day quote
Other OTC
|
||
| - USD | - |
|
| 07-01 | FDA Grants Tentative Approval for ANDA 212581 Azelaic Acid Topical Foam | CI |
| 25/06/24 | Taro Pharmaceutical Industries Ltd.(NYSE:TARO) dropped from S&P Global BMI Index | CI |
| Manager | Title | Age | Since |
|---|---|---|---|
William Coote
DFI | Director of Finance/CFO | 71 | 01/12/2021 |
Richard Glaze
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Hagai Reingold
COO | Chief Operating Officer | - | 01/01/2002 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 01/09/2010 | |
James Kedrowski
BRD | Director/Board Member | 74 | 18/05/2011 |
| Chairman | 70 | 23/09/2010 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.32% | +3.04% | +55.44% | +120.33% | 1,056B | |
| -0.12% | -0.47% | +44.48% | +72.67% | 645B | |
| +0.05% | -0.39% | +14.04% | +78.10% | 465B | |
| -1.74% | -0.47% | +75.61% | +43.73% | 368B | |
| -0.49% | -4.24% | +33.82% | +40.21% | 335B | |
| -0.23% | +2.57% | +20.48% | +29.18% | 275B | |
| -0.76% | -0.72% | +10.36% | +12.69% | 255B | |
| -0.09% | +4.27% | +50.05% | +59.00% | 229B | |
| -0.67% | -0.70% | +35.42% | +102.85% | 188B | |
| Average | -0.42% | +0.12% | +37.74% | +62.09% | 423.98B | |
| Weighted average by Cap. | -0.23% | +0.30% | +41.75% | +74.40% |
Employees
-
Sector
Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
